This core provides the overall management and administrative support for the Program Project grant, mainly related to the multicenter selective lymphadenectomy trials (MSLT) I and MSLT-II, which are at the heart of the entire grant. The John Wayne Cancer Institute (JWCI) database, which includes data on about 14,000 patients who are not enrolled in the MSLT studies, also operates under Core B and supports studies proposed in Projects I, II, and III. In addition, this core coordinates the collection and management of patient specimens (serum and tumor tissue). Finaly, Core B also provides the support for the overall administration of the Program Project, an important part for the integrity of the grant. To consolidate the core activities around the multicenter clinical trials, in this renewal, we conceived a large, complex core that combines the duties of the past Cores B and C (?Research Support? and ?Administrative Service and Multicenter Trial Operations Center?, respectively) and provides essential support to all projects. This consolidation was possible only due to the strong unity of this grant around the multicenter clinical trials MSLT-I and MSLT-II, around which gravitate all three projects and cores.
the specific aims of Core B are: 1) to fulfill all the duties and responsibilities of a multicenter trials operations center for MSLT-I and MSLT-II, including the MSLT-I and -II databases administration;2) to support the JWCI databse administration;3) to sustain the collection, processing, archiving, and retrieval of serum and tumor tissue specimens from the MSLT and JWCI sites; and 4) to provide administration to the individual projects and cores of the Program Project. In conclusion, this large and complex administrative core concentrates the grant administration, multicenter clinical trial operations, JWCI database administration, and the collection of important specimens supporting aims in all projects of the grant.
The main functions of Core B are to support a) the administration of this Program Project through the years 28 to 32, b) the smooth running of two international multicenter clinical trials, MSLT-I and MSLT-II, c) the administration of the JWCI database (-14,000 patients), and d) to sustain collection and archival of certain specimens from MSLT sites and the JWCI clinic. All projects directly rely on this complex support of Core B.
|Ozao-Choy, Junko; Lee, Delphine J; Faries, Mark B (2014) Melanoma vaccines: mixed past, promising future. Surg Clin North Am 94:1017-30, viii|
|Chiu, Connie G; Nakamura, Yoshitaka; Chong, Kelly K et al. (2014) Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clin Chem 60:873-85|
|Marzese, Diego M; Scolyer, Richard A; Roqué, Maria et al. (2014) DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro Oncol 16:1499-509|
|Greenberg, Edward S; Chong, Kelly K; Huynh, Kelly T et al. (2014) Epigenetic biomarkers in skin cancer. Cancer Lett 342:170-7|
|Tanaka, Ryo; Donovan, Nicholas C; Yu, Qiang et al. (2014) Tumor necrosis factor-* and apoptosis induction in melanoma cells through histone modification by 3-deazaneplanocin A. J Invest Dermatol 134:1470-2|
|Yang, James C; Sherry, Richard M (2014) MSLT-I-response of clinical trial investigators. Nat Rev Clin Oncol 11:|
|Nelson, Michael D; Rader, Florian; Tang, Xiu et al. (2014) PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. Neurology 82:2085-91|
|Marzese, Diego M; Scolyer, Richard A; Huynh, Jamie L et al. (2014) Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet 23:226-38|
|Morton, Donald L; Thompson, John F; Cochran, Alistair J et al. (2014) Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370:599-609|
|Marzese, Diego M; Hirose, Hajime; Hoon, Dave S B (2013) Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. Expert Rev Mol Diagn 13:827-44|
Showing the most recent 10 out of 232 publications